In this study, Canadian researchers found that dabigatran was as effective as warfarin in preventing strokes. In addition, the lower dose of dabigatran caused less bleeding than warfarin. At the higher dose, the risk of bleeding was the same for both drugs, the researchers reported.
While not yet approved for use in the United States, dabigatran has been approved in Europe to prevent clotting in people who have had hip or knee replacement surgery.
For more information on heart attacks, visit the American Heart Association.
SOURCES: Robert A. Harrington, M.D., director, Duke Clinical Research Institute, Duke University, Durham, N.C.; Lars Wallentin, M.D., Ph.D., professor, cardiology, Uppsala Clinical Research Center, University Hospital, Sweden; Gregg C. Fonarow, M.D., professor, cardiology, University of California, Los Angeles; Byron Lee, M.D., associate professor, cardiology, University of California San Francisco; Albert Schomig, M.D., department of cardiology, Deutsches Herzzentrum Mnchen, Munich, Germany; Aug. 30, 2009, New England Journal of Medicine, online
All rights reserved